Antibody-Drug Conjugates for Locally Advanced and Metastatic Urothelial Carcinoma: A Systematic Review and - Takeaways - MDSpire

Antibody-Drug Conjugates for Locally Advanced and Metastatic Urothelial Carcinoma: A Systematic Review and

  • By

  • Wei Zhang

  • Haowen Wu

  • Langkun Wang

  • Hang Xu

  • Tianhai Lin

  • Ping Tan

  • Peng Zhang

  • Xiaonan Zheng

  • June 1, 2026

  • 0 min

Share

  • 1

    Urothelial carcinoma (UC) poses significant health challenges, with high recurrence rates and limited treatment options for cisplatin-ineligible patients.

  • 2

    Antibody-drug conjugates (ADCs) target specific proteins in UC, enhancing drug delivery while minimizing damage to healthy tissues.

  • 3

    This review integrates data from various studies to assess the efficacy of ADCs in treating locally advanced and metastatic UC.

  • 4

    The study employs advanced statistical methods to analyze clinical outcomes and identify factors influencing treatment effectiveness.

  • 5

    Findings highlight the need for careful translation of clinical trial results into routine practice for diverse patient populations.

Original Source(s)

Antibody-Drug Conjugates for Locally Advanced and Metastatic Urothelial Carcinoma: A Systematic Review and

  • by Wei Zhang, Haowen Wu, Langkun Wang, Hang Xu, Tianhai Lin, Ping Tan, Peng Zhang, Xiaonan Zheng

  • June 1, 2026

Related Content

Target receptor expression dictates the selective intra-tumoral targeting of CD8+ T cells by eciskafusp alfa in matched PBMCs and TILs from CPI-naïve patients

Gastric-type endocervical adenocarcinoma with Peutz-Jeghers syndrome: a case report and literature review

Percutaneous nephrostomy as a marker of clinical vulnerability in non-metastatic muscle-invasive bladder cancer: prognostic and infectious implications